Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, November 19, presented his laboratory's research on the new field of study called "Connectivity" at the launch of the MINDlink Foundation. [More]

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued Neuromed a letter extending its review of the New Drug Application (NDA) for the product candidate Exalgo™ (hydromorphone HCl) extended-release tablets by three months. [More]

Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances. [More]

The Partnership to Improve Patient Care (PIPC) today applauded Senator Reid’s Patient Protection and Affordable Care Act for including strong patient-centered comparative effectiveness research (CER) language. The CER language is based on the approach taken by Senators Baucus and Conrad in their CER bill (S. 1213), which is supported by over 100 organizations across the country, representing patients, providers, people with disabilities, and minority health organizations. [More]

To help bring greater certainty to the measurement of medication levels in a patient's bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs). [More]

Dr. Donald Weaver, a Halifax researcher with unmatched credentials, received the Prix Galien Research Award at a ceremony in Ottawa last night. Known as the Nobel Prize of pharmaceutical research, this award is the highest distinction worldwide for biopharmaceutical work, and the most prestigious in the field of Canadian pharmaceutical research and innovation. [More]

There is good news for women with multiple sclerosis (MS) who are pregnant or thinking about becoming pregnant. A new study shows that pregnant women with multiple sclerosis are only slightly more likely to have cesarean deliveries and babies with a poor prenatal growth rate than women who do not have MS. [More]

A recent study determined there is a significant risk of seizure for individuals who currently smoke cigarettes. Boston-based researchers from Brigham and Women's Hospital and Harvard Medical School also found that long-term, moderate intake of caffeine or alcohol does not increase the chance of having a seizure or developing epilepsy. [More]

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts. [More]

Stroke researchers at the Methodist Neurological Institute in Houston are the only ones in Texas to offer a novel device that might extend the acute stroke treatment window from three hours to 24. [More]

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs). [More]

Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, with staff from the United States Food and Drug Administration (FDA). [More]

Neurologix, Inc., a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the third quarter and nine months ended September 30, 2009. [More]

Catalyst Pharmaceutical Partners, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]